CLINICAL_TRIALS trial_result · 2018-06-04

Clinical Trial Update: Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 3]

Phase 3 results update on MCI-186 (edaravone) in amyotrophic lateral sclerosis, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Tanabe Pharma Corporation | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: COMPLETED | Results posted: 2018-06-04